title: Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia.
abstract: Epigenetic drugs like histone deacetylase inhibitors (HDACi) and DNA-methyltransferase inhibitors (DNMTi) have been shown to be effective against a variety of tumor entities. Among different molecular anticancer activities of epigenetic active substances, up-regulation of natural killer (NK) cell ligands was described to contribute to an enhanced NK cell-mediated killing of tumor cell lines. So far, no data is available on this effect in childhood acute lymphoblastic leukemia. We investigated the effect of two HDACi [vorinostat, valproic acid (VPA)] and two DNMTi (azacytidine, decitabine) on the viability, expression of NK ligands, and NK susceptibility of the pre-B-cell-ALL cell line MHH-CALL-4. Whereas vorinostat, azacytidine, and decitabine directly reduced viability of the cell line, VPA had no direct cytotoxic effect. NKG2D-ligands were expressed only at very low levels and not affected by epigenetic treatment. Higher expression was found for the DNAM-1 ligands with significant up regulation of CD112 after treatment with VPA (p = 0.02). No significant increase in lysis mediated by resting NK cells could be observed, whereas incubation of target cells with decitabine resulted in a significant increase in lysis mediated by IL-2 activated NK cells (p = 0.0051, p = 0.06 for azacytidine). Vorinostat and VPA could increase the lysis by expanded NK cells which was statistically not significant due to high inter-individual variability. Furthermore, HDACi but not DNMTi reduced the NK-mediated lysis of MHH-CALL-4 after incubation of effector cells. In conclusion, there is a synergistic effect between epigenetic drugs and NK cells against MHH-CALL-4 which is not as strong as in other tumor entities. In situations where NK-mediated control of leukemia is assumed or wanted, a sophisticated combination of single epigenetic drugs and ex vivo expanded NK cells is needed to maximize the synergistic effect of both treatment strategies and DNMTIs may be preferred based on the direct inhibitory effect of HDACi on NK cell cytotoxicity.
authors: Department of Pediatric Hematology and Oncology, University Children's Hospital, Eberhard Karls University Tuebingen Tuebingen, Germany.
authors: Matthias Manuel
authors: MM
authors: Pfeiffer
authors: Helen
authors: H
authors: Burow
authors: Sabine
authors: S
authors: Schleicher
authors: Rupert
authors: R
authors: Handgretinger
authors: Peter
authors: P
authors: Lang
keywords: DNMTi; HDACi; NK cells; immunotherapy; pediatric lymphoblastic leukemia
references: Blood. 2008 Feb 1;111(3):1428-36
references: 17993609
references: FEBS Lett. 2007 Apr 3;581(7):1317-22
references: 17349632
references: Oncogene. 2009 Jun 25;28(25):2370-82
references: 19430493
references: Haematologica. 2010 Aug;95(8):1381-8
references: 20145268
references: Best Pract Res Clin Haematol. 2011 Sep;24(3):403-11
references: 21925093
references: Int J Cancer. 2011 Jun 15;128(12):2911-22
references: 20960460
references: Annu Rev Immunol. 2005;23:225-74
references: 15771571
references: Bone Marrow Transplant. 2001 Apr;27(8):777-83
references: 11477433
references: Leukemia. 2010 Mar;24(3):552-62
references: 20072153
references: J Leukoc Biol. 2012 Feb;91(2):321-31
references: 22124136
references: Br J Haematol. 2006 Jul;134(2):196-201
references: 16846478
references: Leuk Res. 2002 May;26(5):495-502
references: 11916526
references: Br J Haematol. 2002 Jun;117(4):821-7
references: 12060116
references: J Immunol. 2004 Jan 1;172(1):644-50
references: 14688377
references: Blood. 2012 May 31;119(22):5201-10
references: 22496163
references: Leukemia. 2006 Aug;20(8):1435-6
references: 16810202
references: Leuk Res. 2005 Jul;29(7):739-48
references: 15927669
references: Int J Oncol. 2011 Dec;39(6):1491-9
references: 21805029
references: J Clin Oncol. 2010 Aug 1;28(22):3623-9
references: 20606092
references: Exp Hematol. 2005 Jan;33(1):53-61
references: 15661398
references: Leuk Res. 2007 Oct;31(10):1393-402
references: 17391757
references: Science. 2002 Mar 15;295(5562):2097-100
references: 11896281
references: Blood. 2005 Mar 1;105(5):2066-73
references: 15536144
references: Mol Immunol. 2013 Jul;54(3-4):296-301
references: 23328088
references: Blood. 2003 Feb 15;101(4):1630-6
references: 12393439
references: Annu Rev Immunol. 2001;19:197-223
references: 11244035
references: Br J Haematol. 2007 Jul;138(1):97-100
references: 17555452